Welcome to our dedicated page for Glaukos Corporation news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation stock.
Glaukos Corporation (NYSE: GKOS) is a prominent ophthalmic medical technology company specializing in breakthrough products and procedures aimed at transforming the treatment of glaucoma. As one of the leading causes of blindness globally, glaucoma demands innovative solutions, and Glaukos has pioneered micro-invasive glaucoma surgery (MIGS) to revolutionize traditional management paradigms.
The company's flagship product, the iStent Trabecular Micro-Bypass Stent, launched in the United States in 2012, is celebrated for being the smallest medical device ever approved by the FDA, measuring a mere 1.0 mm long and 0.33 mm wide. This device is designed to reduce intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma when used in conjunction with cataract surgery.
Building on the success of the iStent, Glaukos is developing a comprehensive and proprietary portfolio of injectable micro-scale therapies targeting the entire spectrum of glaucoma disease states and progression. The pipeline includes the iStent SA Trabecular Micro-Bypass System, a two-stent product with a different auto-injection inserter for standalone procedures.
In June 2015, Glaukos successfully completed its initial public offering, and its shares are now publicly traded on the New York Stock Exchange. The company continues to innovate and expand its product offerings, maintaining its position as a leader in the ophthalmic medical technology field.
- Recent achievements include the expansion of their product pipeline and the ongoing development of next-generation MIGS devices.
- Current projects focus on enhancing the efficacy and accessibility of glaucoma treatments worldwide.
- Partnerships with leading ophthalmic institutions and research organizations fuel Glaukos' mission to improve patient outcomes.
Glaukos Corporation remains committed to transforming glaucoma treatment through technological innovation and strategic growth.
Glaukos Corporation (NYSE: GKOS) announced an amended licensing agreement with Intratus, Inc. for the exclusive global license to develop and commercialize Intratus' non-invasive Eyelid Drug Delivery Platform, now including presbyopia treatments. This expands their existing agreement from 2019, which focused on dry eye disease and glaucoma. The platform offers a patient-friendly transdermal approach with promising early human study results. Financial terms were not disclosed, but the partnership aims to enhance Glaukos' portfolio in ophthalmic therapies.
Glaukos Corporation (NYSE: GKOS) will announce its Q1 2021 financial results on Wednesday, May 5, 2021, after market close. A conference call and webcast led by the management team will occur at 1:30 p.m. PDT (4:30 p.m. EDT) on the same day. Glaukos specializes in innovative therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012 with devices like the iStent series. For participation details, please visit investors.glaukos.com.
Glaukos Corporation (NYSE: GKOS) launched two patient-centric initiatives for World Glaucoma Week, aimed at raising awareness of glaucoma. The initiatives include a global education campaign called “Making an iMPACT: Glaucoma Perspectives” featuring interviews with leading physicians and a glaucoma patient. Additionally, Glaukos will collaborate with U.S. eye care institutions to provide free glaucoma screenings. These efforts underline Glaukos' commitment to improving glaucoma treatment and patient education across the globe.
Glaukos Corporation (NYSE: GKOS) announced its management's virtual participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 3:10 p.m. EDT. This event will be available via live and archived webcast on Glaukos' Investors website. Glaukos specializes in medical technology and pharmaceuticals for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices like the iStent series.
Glaukos Corporation (NYSE: GKOS) has appointed Denice Torres and Dr. Leana Wen as new members of its Board of Directors, increasing the board to nine members, eight of whom are independent. The addition aims to enhance the board's expertise as the company continues to expand its global presence in ophthalmic medical technologies. Torres, with over 25 years in healthcare management, previously held leadership roles at Johnson & Johnson, while Dr. Wen is known for her public health advocacy and emergency medicine expertise. Their insights are expected to benefit Glaukos' mission in treating chronic eye diseases.
Glaukos Corporation (GKOS) reported Q4 2020 net sales of $73.2 million, an increase from $65.8 million in Q4 2019. The gross margin stood at approximately 73%, down from 76% year-over-year. For 2020, overall net sales fell 5% to $225.0 million, with a net loss of $120.3 million or ($2.70) per diluted share. Despite losses, the company ended the year with $413.9 million in cash and investments. They forecast a 15%-20% increase in Q1 2021 net sales compared to the previous year.
Glaukos Corporation (NYSE: GKOS) announced positive results from its Phase 3 trial of iLink™ Epi-on therapy for treating keratoconus. The trial met its primary efficacy endpoint, showing a statistically significant improvement in maximum corneal curvature (Kmax) at 6 months. The treatment group exhibited a Kmax improvement of -1.0D (p = 0.0004), indicating the therapy's effectiveness. With 98% of placebo patients opting for Epi-on after the trial, safety was affirmed as 97% completed the study. Glaukos aims for FDA submission in 2022 and anticipates approval in 2023, capitalizing on this promising therapy.
Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, after market closure. A conference call to discuss these results will take place at 1:30 p.m. PST (4:30 p.m. EST) on the same day. Investors can access the live webcast through the company’s website. Glaukos specializes in innovative treatments for glaucoma and other ocular conditions, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices such as the iStent® and iStent inject®.
Glaukos Corporation (NYSE: GKOS) announced promising 12-month data from its U.S. Investigational Device Exemption pivotal trial for the iStent infinite Trabecular Micro-Bypass System, indicating significant effectiveness in lowering intraocular pressure (IOP) in patients with open-angle glaucoma. In the trial, 76% of participants experienced a 20% or greater reduction in mean IOP, with over 50% achieving a ≥30% reduction. The study reported a favorable safety profile, with no serious complications noted. Glaukos plans to submit for FDA approval of the device, aiming for a late 2021 target.
FAQ
What is the current stock price of Glaukos Corporation (GKOS)?
What is the market cap of Glaukos Corporation (GKOS)?
What is Glaukos Corporation?
What is the iStent Trabecular Micro-Bypass Stent?
When did Glaukos go public?
What is MIGS?
What is the iStent SA?
What recent achievements has Glaukos made?
What is the significance of Glaukos' products?
Who are Glaukos' partners?
What is Glaukos' mission?
How does Glaukos continue to innovate?
